Krabbe Disease Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | AlaMab Therapeutics, Zentalis Pharmaceuticals, Isofol Medical, Merck, Eisai
According to DelveInsight, the Krabbe Disease pipeline includes over eight leading companies actively engaged in developing more than eight treatment therapies for the condition.
Krabbe Disease Overview:
Krabbe disease includes a spectrum of disorders, ranging from infantile-onset—marked by severe symptoms like extreme irritability, muscle stiffness (spasticity), and developmental delays appearing before 12 months of age—to later-onset forms, which can emerge anytime after the first year of life, even into the seventh decade. Traditionally, enzyme activity testing has shown that 85%–90% of symptomatic cases are infantile-onset, with only 10%–15% being later-onset. However, findings from newborn screening (NBS) suggest that later-onset cases may be more common than previously thought. Infantile-onset typically starts with normal development, followed by rapid neurological deterioration, and an average life expectancy of about 24 months (with a range from 8 months to 9 years). Later-onset forms of the disease are more variable in both symptoms and disease progression.
Request for a detailed insights report on Krabbe Disease pipeline insights
“Krabbe Disease Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Krabbe Disease Therapeutics Market.
Key Takeaways from the Krabbe Disease Pipeline Report
-
DelveInsight’s Krabbe Disease pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Krabbe Disease treatment.
-
In January 2025, The FDA awarded breakthrough therapy designation (BTD) to GSK5764227 (GSK’227) for treating adult patients with relapsed or refractory Krabbe Disease who have experienced disease progression after receiving at least two previous treatment regimens.
-
Key Krabbe Disease companies such as Forge Biologics, Passage Bio, Sanbio, Polaryx, Gain Therapeutics, and others are evaluating new drugs for Krabbe Disease to improve the treatment landscape.
-
Promising Krabbe Disease pipeline therapies in various stages of development include FBX-101, PBKR03, and others.
Krabbe Disease Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the key companies that are developing therapies in the Krabbe Disease Market.
-
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Krabbe Disease treatment.
-
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Krabbe Disease market.
Download our free sample page report on Krabbe Disease pipeline insights
Krabbe Disease Emerging Drugs
-
FBX-101: Forge Biologics
-
PBKR03: Passage Bio
Krabbe Disease Companies
Approximately eight major companies are actively working on developing treatments for Krabbe disease. Of these, Passage Bio has the most advanced drug candidates, currently in Phase I/II of clinical development.
DelveInsight’s report covers around 22+ products under different phases of clinical development like
-
Late stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Krabbe Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intravenous
-
Subcutaneous
-
Oral
-
Intramuscular
Krabbe Disease Products have been categorized under various Molecule types such as
-
Monoclonal antibody
-
Small molecule
-
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Krabbe Disease Therapies and Key Companies: Krabbe Disease Clinical Trials and advancements
Krabbe Disease Pipeline Therapeutic Assessment
• Krabbe Disease Assessment by Product Type
• Krabbe Disease By Stage
• Krabbe Disease Assessment by Route of Administration
• Krabbe Disease Assessment by Molecule Type
Download Krabbe Disease Sample report to know in detail about the Krabbe Disease treatment market @ Krabbe Disease Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. Krabbe Disease Current Treatment Patterns
4. Krabbe Disease – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Krabbe Disease Late-Stage Products (Phase-III)
7. Krabbe Disease Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Krabbe Disease Discontinued Products
13. Krabbe Disease Product Profiles
14. Krabbe Disease Key Companies
15. Krabbe Disease Key Products
16. Dormant and Discontinued Products
17. Krabbe Disease Unmet Needs
18. Krabbe Disease Future Perspectives
19. Krabbe Disease Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Krabbe Disease Pipeline Reports Offerings
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
